Festive Brain Teaser
In blood cells I begin, though symptoms are few,
Mutations arise, and resistance can brew.
Tyrosine inhibitors may slow the fight,
But a shift in the course can alter the light.
What am I?
Click to reveal the answer:
Most Read Interview in 2024
Sara Tolaney, Chief of the Division of Breast Oncology, Dana-Farber Cancer Institute
Sara Tolaney shares her journey into oncology, groundbreaking work in HER2+ and triple-negative breast cancers, and how antibody-drug conjugates are transforming treatment.